PMID- 27818660
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231111
IS  - 1664-3224 (Print)
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 7
DP  - 2016
TI  - Unraveling the Role of Allo-Antibodies and Transplant Injury.
PG  - 432
LID - 432
AB  - Alloimmunity driving rejection in the context of solid organ transplantation can 
      be grossly divided into mechanisms predominantly driven by either T cell-mediated 
      rejection (TCMR) and antibody-mediated rejection (ABMR), though the co-existence 
      of both types of rejections can be seen in a variable number of sampled grafts. 
      Acute TCMR can generally be well controlled by the establishment of effective 
      immunosuppression (1, 2). Acute ABMR is a low frequency finding in the current 
      era of blood group and HLA donor/recipient matching and the avoidance of 
      engraftment in the context of high-titer, preformed donor-specific antibodies. 
      However, chronic ABMR remains a major complication resulting in the untimely loss 
      of transplanted organs (3-10). The close relationship between donor-specific 
      antibodies and ABMR has been revealed by the highly sensitive detection of human 
      leukocyte antigen (HLA) antibodies (7, 11-15). Injury to transplanted organs by 
      activation of humoral immune reaction in the context of HLA identical transplants 
      and the absence of donor specific antibodies (17-24), strongly suggest the 
      participation of non-HLA (nHLA) antibodies in ABMR (25). In this review, we 
      discuss the genesis of ABMR in the context of HLA and nHLA antibodies and 
      summarize strategies for ABMR management.
FAU - Matsuda, Yoshiko
AU  - Matsuda Y
AD  - Department of Surgery, University of California San Francisco , San Francisco, CA 
      , USA.
FAU - Sarwal, Minnie M
AU  - Sarwal MM
AD  - Department of Surgery, University of California San Francisco , San Francisco, CA 
      , USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20161021
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
PMC - PMC5073555
OTO - NOTNLM
OT  - HLA antibody
OT  - antibody-mediated rejection
OT  - donor-specific HLA antibody
OT  - humoral immune system
OT  - in vitro B cell assay
OT  - non-HLA antibody
EDAT- 2016/11/08 06:00
MHDA- 2016/11/08 06:01
PMCR- 2016/01/01
CRDT- 2016/11/08 06:00
PHST- 2016/06/03 00:00 [received]
PHST- 2016/10/03 00:00 [accepted]
PHST- 2016/11/08 06:00 [entrez]
PHST- 2016/11/08 06:00 [pubmed]
PHST- 2016/11/08 06:01 [medline]
PHST- 2016/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2016.00432 [doi]
PST - epublish
SO  - Front Immunol. 2016 Oct 21;7:432. doi: 10.3389/fimmu.2016.00432. eCollection 
      2016.